Analysis on changes in anti-tumor drug in WHO essential model list and the effect on revision of national essential medicines list

doi:10.3969/j.issn.1672-3384.2021.04.011

YAN Jia-qing, LIU Min, MA Ying-lin, LE Kai-di, DONG Bin, LI Guo-hui

Clinical Medication Journal ›› 2021, Vol. 19 ›› Issue (4) : 54-57.

PDF(527 KB)

Clinical Medication Journal ›› 2021, Vol. 19 ›› Issue (4) : 54-57. DOI: 10.3969/j.issn.1672-3384.2021.04.011

Original Article

Analysis on changes in anti-tumor drug in WHO essential model list and the effect on revision of national essential medicines list

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2021, 19(4): 54-57 https://doi.org/10.3969/j.issn.1672-3384.2021.04.011

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(527 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2020-09-25	2021-04-11
Issue Date
2021-04-11

Please choose a citation manager

Content to export